

SHORT REPORT

# Failure to detect DUP25 in lymphoblastoid cells derived from patients with panic disorder and control individuals representing European and American populations

Guanshan Zhu<sup>1,2,7</sup>, Oliver Bartsch<sup>3,7</sup>, Cristina Skrypnik<sup>3,4</sup>, Alessandro Rotondo<sup>5</sup>, Longina A Akhtar<sup>1</sup>, Claudia Harris<sup>1</sup>, Matti Virkkunen<sup>6</sup>, Giovanni Cassano<sup>5</sup>, David Goldman<sup>\*,1</sup>

<sup>1</sup>Laboratory of Neurogenetics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892, USA; <sup>2</sup>Changhai Hospital, Shanghai 200433, PR China; <sup>3</sup>Institute of Clinical Genetics, Dresden University of Technology, 01307 Dresden, Germany; <sup>4</sup>Department of Genetics, University of Oradea, 3700 Oradea, Romania; <sup>5</sup>Department of Psychiatry, University of Pisa, Pisa 56100, Italy; <sup>6</sup>Department of Psychiatry, University of Helsinki, Helsinki, Finland

Investigation of the co-occurrence of panic and phobic disorders with joint laxity led to the identification of interstitial duplications involving human chromosome 15q24–26 (named 'DUP25') in a Spanish population. DUP25 was observed in 97% of patients and in 7% of control individuals. In the present study, we used two different methods to detect DUP25: high-throughput molecular gene dosage analysis and fluorescence *in situ* hybridization (FISH). We evaluated 56 lymphoblastoid cell lines derived from 26 unrelated patients with panic disorder obtained from several European and American populations and 30 normal controls. We could not find any cell line showing a result consistent with DUP25. These data do not support any association of DUP25 with panic disorder.

*European Journal of Human Genetics* (2004) 12, 505–508. doi:10.1038/sj.ejhg.5201181

Published online 31 March 2004

**Keywords:** chromosomal duplication; panic disorder; fluorescence *in situ* hybridization; real-time PCR

## Introduction

Gratacòs *et al*<sup>1</sup> reported that a polymorphic genomic interstitial duplication of 15q24–q26 ('DUP25') was associated with both familial and nonfamilial panic and phobic disorders. The chromosomal analyses were performed in both peripheral blood lymphocytes and sperm. In 70 unrelated patients with an anxiety disorder, DUP25 was

found in 68. Among 189 controls, DUP25 was seen in only 14. The DUP25-positive cells were almost always in the majority, with 59% being the average proportion among positive individuals. These observations are extremely interesting because they represent an association between a genetic difference and common psychiatric disorders. Second, the pattern of DUP25 distribution in families was that of a very common, *de novo* mutation, with mosaicism in affected family members with panic or phobic disorders.

We used two different methods to detect DUP25: high-throughput molecular gene dosage analysis and fluorescence *in situ* hybridization (FISH). We studied 56 lymphoblastoid cell lines derived from 26 unrelated patients with panic disorder and 30 normal controls. Such cell lines are polyclonal and derived from B-lymphocyte

\*Correspondence: Dr D Goldman, Laboratory of Neurogenetics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892, USA. Tel: +1 301 443 0059; Fax: +1 301 443 8579; E-mail: dgneuro@box-d.nih.gov

<sup>7</sup>These authors equally contributed to this study.

Received 13 August 2003; revised 16 January 2004; accepted 6 February 2004

precursors. We found no cell line showing a result consistent with DUP25.

## Materials and methods

### Lymphoblastoid cell lines

Lymphoblastoid cell lines were prepared using a standard Epstein–Barr virus transformation protocol and stored at  $-140^{\circ}\text{C}$  until use. A total of 56 lymphoblastoid cell lines were examined for DUP25, including 26 derived from unrelated patients with panic disorder. The panic disorder sample consisted of 10 Italian Caucasians, seven American Caucasians, five Finnish Caucasians and four American Indians (16 female and, 10 male subjects, aged from 20 to 68 years, Table 1). A total of 30 unrelated normal controls included 10 Italian Caucasians and 20 American Caucasians (16 female and, 14 male subjects, aged from 15 to 80 years). Subjects received a structured psychiatric interview: either the SADS-L (American Indians) or the SCID (all others). Diagnoses were by DSM-III-R criteria. All patients gave written informed consent to participate in the study. Human research protocols were approved by the Institutional Review Boards of the National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, the National Institute of Mental Health, Bethesda, MD, the University of Helsinki, Helsinki, the University of Pisa, Pisa, and by the Office for Protection From Research Risks, Bethesda, MD. DNA was isolated for gene dosage analysis and chromosomes were prepared for FISH.

### Real-time quantitative PCR for gene dosage analysis

Gene dosage analysis of *NTRK3*, a candidate gene identified within DUP25<sup>1</sup> was performed using real-time quantitative PCR, by modification of a previously reported method.<sup>2</sup> Fluorescent signals for a representative DUP25 sequence and a control sequence were generated using specific probes labeled with a signal dye and a quencher dye – with liberation of signal by the 5' nuclease cleavage of the nucleotide coupled to the signal dye. *NTRK3* and a control sequence (serotonin transporter gene, *5-HTT*) located on chromosome 17 were coamplified, and amplification of both loci was simultaneously monitored in the same reaction well in real time. Primers and probe for *NTRK3* were: forward, 5'-CTGGAGCACTGCATCGAGTTT-3'; reverse, 5'-GAAATCTCTCCCTCTTGGTAGTATTCC-3'; and probe, 5'-(VIC) CGCTGCACTGGCTGCACAATG (TAMRA)-3'. Primers and probe for *5-HTT* were: forward, 5'-TGGC-CTGGGCGC TATACTAC-3'; reverse, 5'-GTTGTCTCGGAGAAGTAATT GGT-3'; and probe, 5'-(FAM) ACCAGCTGCAAGAACTCC TGGAACA (TAMRA)-3'. The 25- $\mu\text{l}$  reaction volume contained 2  $\mu\text{l}$  (100ng) genomic DNA, 1  $\mu\text{M}$  of each primer, 0.2  $\mu\text{M}$  of each dual-labeled probe, and further components supplied in TaqMan Universal PCR Master Mix (Perkin–Elmer), corresponding to 3.5 mM  $\text{MgCl}_2$ , 100  $\mu\text{M}$  dNTPs, 0.025 U/ $\mu\text{l}$  AmpliTaq Gold, and 0.01 U/ $\mu\text{l}$  Amp Erase. Cycling conditions were as follows: incubation for 2 min at  $50^{\circ}\text{C}$  to permit Amp Erase activity, and for 10 min at

**Table 1** Patients with panic disorder

| Patient | Population | Age (year) | Sex | DSM-III-R Diagnoses   |
|---------|------------|------------|-----|---|
| 1       | Italian    | 37         | F   | Panic disorder with agoraphobia, major depression   |
| 2       | Italian    | 63         | M   | Panic disorder with agoraphobia   |
| 3       | Italian    | 46         | F   | Panic disorder without agoraphobia, social phobia, obsessive–compulsive disorder, dysthymia |
| 4       | Italian    | 43         | F   | Panic disorder with agoraphobia, major depression   |
| 5       | Italian    | 20         | F   | Panic disorder, social phobia, major depression   |
| 6       | Italian    | 62         | M   | Panic disorder with agoraphobia, simple phobia  |
| 7       | Italian    | 33         | F   | Panic disorder, major depression  |
| 8       | Italian    | 42         | F   | Panic disorder without agoraphobia, bipolar II disorder                                     |
| 9       | Italian    | 55         | M   | Panic disorder without agoraphobia, major depression  |
| 10      | Italian    | 24         | M   | Panic disorder without agoraphobia, simple phobia   |
| 11      | American   | 26         | F   | Panic disorder, phobia  |
| 12      | American   | 30         | F   | Panic disorder, major depression  |
| 13      | American   | 41         | F   | Panic disorder, major depression  |
| 14      | American   | 40         | F   | Panic disorder, major depression  |
| 15      | American   | 23         | F   | Panic disorder, major depression, obsessive compulsive disorder                             |
| 16      | American   | 42         | F   | Panic disorder, major depression  |
| 17      | American   | 36         | M   | Panic disorder, major depression  |
| 18      | Finnish    | 39         | M   | Panic disorder  |
| 19      | Finnish    | 25         | M   | Panic disorder  |
| 20      | Finnish    | 45         | F   | Panic disorder, alcohol dependence  |
| 21      | Finnish    | 41         | M   | Panic disorder  |
| 22      | Finnish    | 56         | M   | Panic disorder, major depression, simple phobia, alcohol dependence                         |
| 23      | Am Indian  | 51         | F   | Panic disorder, major depression, phobia  |
| 24      | Am Indian  | 68         | M   | Panic disorder  |
| 25      | Am Indian  | 48         | F   | Panic disorder, major depression, phobia  |
| 26      | Am Indian  | 27         | F   | Panic disorder, major depression, phobia, post-traumatic stress disorder                    |

95°C for AmpliTaq Gold activation and DNA denaturation, followed by 40 cycles of 1 min at 60°C and 15 s at 95°C. The ratio of the target *vs* control sequence was determined by the difference in threshold cycle value ( $\Delta\text{Ct}$ ) at fluorescence intensity threshold  $\Delta\text{Rn} = 0.03$ . Triplicate assays were performed for each sample.

### FISH testing


FISH was performed on all Italian patients (10) and controls (10), and on 16 other panic disorder patients. Slides for FISH were prepared using standard procedures. A 640 kb YAC (957b4) which maps to the DUP25 region<sup>1</sup> was selected as probe for FISH. The YAC DNA was processed as described elsewhere.<sup>3,4</sup> YAC DNA was amplified using a degenerate oligonucleotide primed PCR (DOP-PCR) protocol: 25  $\mu\text{l}$  reaction mix contained 1  $\mu\text{l}$  template DNA (about 50 ng), 2.5  $\mu\text{l}$  10  $\times$  Buffer, 3.5 mmol/l  $\text{MgCl}_2$ , 0.25 mmol/l dNTP, 0.05 U/ $\mu\text{l}$  *Taq* polymerase, 2  $\mu\text{mol/l}$  primer (5'-CCGACTCGAGNNNNNNATGTGG-3'). The PCR was performed for 35 cycles with a predenaturation temperature of 94°C for 1 min, a denaturation temperature of 94°C for 1 min, an annealing temperature of 56°C for 1 min, and an extension temperature of 72°C for 4 min for every single cycle, and ending at 72°C for 10 min. Probe labeling with tetramethylrhodamine (TMR) was performed by DOP-PCR: 10  $\mu\text{l}$  reaction mix consisted of 1  $\mu\text{l}$  product from the PCR above, 1  $\mu\text{l}$  10  $\times$  Buffer, 4 mmol/l  $\text{MgCl}_2$ , 0.2 mmol/l d(ACG)TP, 0.15 mmol/l dTTP, 0.05 mmol/l TMR-6-dUTP, 0.1 U/ $\mu\text{l}$  *Taq* polymerase, and 6  $\mu\text{mol/l}$  degenerate oligonucleotide primer with the same sequence as above. The PCR was performed for 25 cycles with a predenaturation temperature of 95°C for 3 min, a denaturation temperature of 94°C for 1 min, an annealing temperature of 56°C for 1 min, and an extension temperature of 72°C for 2 min for every single cycle, and ending at 72°C for 10 min. Products were cut with DNase I (0.2 U/ml, 37°C 3 min) and mixed with Cot-1 DNA (20  $\mu\text{g}$ ). Labeled probes were purified by cold ethanol precipitation, and dissolved in 8  $\mu\text{l}$  1  $\times$  TE. The additional FISH experiment on patient No. 25 who showed DUP25 look-alike signals with YAC 957b4 in a subset of metaphases was performed using cosmids c251-3 and t216-1 from Gratacòs *et al*<sup>1</sup> with a previously described amplification and labeling procedure.<sup>4</sup>

**FISH:** A mixture of 1.6  $\mu\text{l}$  probe solution and 5.4  $\mu\text{l}$  Hybrisol VI (Oncor, Gaithersburg, MD, USA) was pipetted onto the slide containing target metaphases. The slide was covered with a coverslip and rubber cement and heated at 72°C for 5 min, incubated at 37°C for 48 h, washed with 50°C formamide/2  $\times$  SSC solution at 42°C for 7 min, washed with 0.4  $\times$  SSC solution at 42°C for 10 min, and stained with DAPI. Microscopy was performed with an Axiophot epifluorescence microscope (Carl Zeiss, Göttingen, Germany) and the ISIS digital imaging system (MetaSystems, Altlußheim, Germany).

### Results

By quantitative gene dosage analysis, we observed  $\Delta\text{Ct} = 0.03 \pm 0.16$  for control samples and  $\Delta\text{Ct} = 0.00 \pm 0.15$  for patient samples, indicating no difference for the fluorescent signal for the DUP25 locus and the control locus on chromosome 17. The highest  $\Delta\text{Ct}$  was observed in Patient No. 25 with  $\Delta\text{Ct} = 0.3$  (from two independent triplicate measurements), yielding a ratio of 1.23:1 for *NTRK3* to the control locus (Figure 1).

For FISH of 26 patients and 10 controls, 20–49 metaphases (mean =  $28 \pm 5$ , median = 30) from each cell line were analyzed for DUP25 by one cytogeneticist (CS) and confirmed by a well-experienced molecular cytogeneticist (OB). One patient (No. 25) showed DUP25 look-alike signals. In this individual, 19/49 (37%) analyzed cells seemed to show four-spot or three-spot hybridization signals on one chromosome 15 homologue and a normal hybridization signal on the other chromosome 15 homologue, the other 30 analyzed cells showed the usual pattern of positive hybridization to both chromosome 15 homologues and no evidence of duplication of the region. In other patients and in all controls, the number of cells that were abnormal was few or none. In total, 11 patients and four controls showed a few (1, 2 or 3) cells with four hybridization spots on one chromosome 15 homologue and a normal twin-spot signal on the other homologue. However, based on the low frequency of 4-spot-cells per individual, we interpreted these observations as split-signal artefacts (normal cells). Possible explanations for the observed split-signals include preparation artefacts such as DNA fibers leaking out of their chromosomal position and/or the distribution of single-copy *vs* repetitive sequences within the YAC probe used. Since patient No. 25 was also the subject in which the highest  $\Delta\text{Ct}$  was observed by repeated quantitative gene dosage analysis, we repeated FISH experiments on this particular case using two cosmid



**Figure 1** Ratios of a DUP25-specific locus to a control locus in patients with panic disorder and normal controls.

probes, c251-3 and t216-1, that have been used by Gratacòs *et al.*<sup>1</sup> A total of 20 metaphases were evaluated for each probe. Only one cell hybridized with probe c251-3 showed a pattern compatible with DUP25 and the other 39 cells showed normal signals. This result substantially excluded the existence of DUP25 in any individual of our sample.

## Discussion

The results of this study do not support the presence of DUP25 in patients with panic disorder.<sup>1</sup> Our findings are consistent with Tabiner *et al.*,<sup>5</sup> who detected DUP25 in none of 16 patients with panic disorder and 40 control individuals. In contrast, Gratacòs *et al.*<sup>1</sup> had found that 97% of panic disorder patients had DUP25 and the average percentage of metaphases with DUP25 was 59%.

Three of the lymphoblastoid cell lines reported by Gratacòs *et al.*<sup>1</sup> as positive for DUP25 have been studied for a second time: independently by Tabiner *et al.*<sup>5</sup> and again by Gratacòs *et al.*<sup>1</sup> Tabiner *et al.*<sup>5</sup> were not able to detect DUP25 in these cell lines, but Gratacòs *et al.*<sup>1</sup> again did. More recently, Weiland *et al.*<sup>6</sup> used multicolor FISH for confirmation of two slides supposed to be DUP25 positive by Gratacòs *et al.*,<sup>1</sup> one made from a lymphoblastoid cell line and the other made directly from lymphocytes. Again, the results were negative. Taken together with our results, it is highly likely that technical problems led Gratacòs *et al.*<sup>1</sup> to overestimate the abundance of DUP25. In our FISH study, we also observed a few DUP25 look-alike cells in about half of individuals, but none with the frequency of DUP25 metaphases reported by Gratacòs *et al.*<sup>1</sup> These FISH results were fully congruent with the quantitative PCR.

Many factors can critically influence FISH. These include chromosome preparation, probe size and content of repetitive DNA sequences within the probe. A short distance between signals in small duplications as occurs with DUP25 makes it most difficult to obtain a clear result with metaphase FISH, unaided by a reliable gene dosage

method as used in this study. Up to now, the observation of Gratacòs *et al.*<sup>1</sup> has not been confirmed by any other group. Instead, accumulating evidence indicates that DUP25 may not actually exist. Further studies combining FISH and gene dosage methods are needed to clarify the existence of DUP25 in different populations and the relationship between DUP25 and panic disorders, or other phenotypes. It would be of great interest if this kind of study could be replicated in the Spanish population.

## Acknowledgements

We thank Dr. Vera Kalscheuer of the Max Planck Institute for Molecular Genetics, Berlin, Germany, for sending DNA of YAC 957b4 and Dr. Mary-Anne Enoch for her assistance in clinical data collection. We also thank Dr. Xavier Estivill and Lluís Armengol for providing DNA of cosmids c251-3 and t216-1.

## References

- 1 Gratacòs M, Nadal M, Martín-Santos R *et al*: A polymorphic genomic duplication on human chromosome 15 is a susceptibility factor for panic and phobic disorders. *Cell* 2001; **106**: 367–379.
- 2 Zimmermann B, Holzgreve W, Wenzel F, Hahn S: Novel real-time quantitative PCR test for trisomy 21. *Clin Chem* 2002; **48**: 362–363.
- 3 Telenius H, Carter NP, Bebb CE, Nordenskjold M, Ponder BA, Tunnacliffe A: Degenerate oligonucleotide-primed PCR: general amplification of target DNA by a single degenerate primer. *Genomics* 1992; **13**: 718–725.
- 4 Bartsch O, Wagner A, Hinkel GK *et al*: FISH studies in 45 patients with Rubinstein–Taybi syndrome: deletions associated with polysplenia, hypoplastic left heart and death in infancy. *Eur J Hum Genet* 1999; **7**: 748–756.
- 5 Tabiner M, Youings S, Dennis N *et al*: Failure to find DUP25 in patients with anxiety disorders, in control individuals, or in previously reported positive control cell lines. *Am J Hum Genet* 2003; **72**: 535–538.
- 6 Weiland Y, Kraus J, Speicher MR: A multicolor FISH assay does not detect DUP25 in control individuals or in reported positive control cells. *Am J Hum Genet* 2003; **72**: 1349–1352.